FES kinases are required for oncogenic FLT3 signaling

Leukemia

Volumn 24, Issue 4, 2010, Pages 721-728

  Voisset, E ^a,b,c   Lopez, S ^a,b,c   Chaix, A ^a,b,c   Georges, C ^a,b,c   Hanssens, K ^a,b,c   Prebet T ^a,b,c   Dubreuil, P ^a,b,c   De Sepulveda, P ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Acute myeloid leukemia; C fes; Flt 3 mutation; FLT3 receptor; Fps

Indexed keywords

CD135 ANTIGEN; MUTANT PROTEIN; PROTEIN KINASE FER; PROTEIN KINASE FES;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 77950921546     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.301     Document Type: Article

References (35)

1. Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program 2006; 1: 178-184.
2. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol 2002; 9: 274-281.
3. Drexler HG, Quentmeier H. FLT3: receptor and ligand. Growth Factors 2004; 22: 71-73.
4. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 2004; 61: 2932-2938.
5. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-665.
6. Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 2004; 103: 267-274.
7. Tickenbrock L, Muller-Tidow C, Berdel WE, Serve H. Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs 2006; 11: 153-165.
8. Choudhary C, Muller-Tidow C, Berdel WE, Serve H. Signal transduction of oncogenic Flt3. Int J Hematol 2005; 82: 93-99.
9. Smithgall TE, Rogers JA, Peters KL, Li J, Briggs SD, Lionberger JM et al. The c-Fes family of protein-tyrosine kinases. Crit Rev Oncog 1998; 9: 43-62.
10. Greer P. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 2002; 3: 278-289.
11. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300: 949.
12. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158.
13. Voisset E, Lopez S, Dubreuil P, De Sepulveda P. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood 2007; 110: 2593-2599.
14. Stirewalt DL, Meshinchi S, Radich JP. Molecular targets in acute myelogenous leukemia. Blood Rev 2003; 17: 15-23.
15. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53: 245-266.
16. Valent P. Systemic mastocytosis. Cancer Treat Res 2008; 142: 399-419.
17. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003; 17: 120-124.
18. Yu H, Maurer F, Medcalf RL. Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 2002; 99: 2810-2818.
19. Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood 2005; 105: 2952-2954.
20. Hjermstad SJ, Peters KL, Briggs SD, Glazer RI, Smithgall TE. Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713). Oncogene 1993; 8: 2283-2292.
21. Rogers JA, Read RD, Li J, Peters KL, Smithgall TE. Autopho-sphorylation of the Fes tyrosine kinase. Evidence for an inter-molecular mechanism involving two kinase domain tyrosine residues. J Biol Chem 1996; 271: 17519-17525.
22. Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res 2006; 66: 3828-3835.
23. Robinson LJ, Xue J, Corey SJ. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 2005; 33: 469-479.
24. Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A et al. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 2007; 21: 403-410.
25. Muller JP, Schonherr C, Markova B, Bauer R, Stocking C, Bohmer FD. Role of SHP2 for FLT3-dependent proliferation and transformation in 32D cells. Leukemia 2008; 22: 1945-1948.
26. Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood 2003; 102: 2969-2975.
27. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379-382.
28. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003; 9: 2140-2150.
29. Pasder O, Shpungin S, Salem Y, Makovsky A, Vilchick S, Michaeli S et al. Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells. Oncogene 2006; 25: 4194-4206.
30. Loriaux MM, Levine RL, Tyner JW, Frohling S, Scholl C, Stoffregen EP et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008; 111: 4788-4796.
31. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111: 4797-4808.
32. Delfino FJ, Stevenson H, Smithgall TE. A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer. J Biol Chem 2006; 281: 8829-8835.
33. Sangrar W, Zirgnibl RA, Gao Y, Muller WJ, Jia Z, Greer PA. An identity crisis for fps/fes: oncogene or tumor suppressor? Cancer Res 2005; 65: 3518-3522.
34. Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 2007; 67: 11368-11376.
35. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.